Molecular Formula | C19H21NO |
Molar Mass | 279.38 |
Density | 1.11±0.1 g/cm3(Predicted) |
Melting Point | 166 °C |
Boling Point | 480.1±45.0 °C(Predicted) |
Appearance | powder |
Color | white to beige |
pKa | 15.87±0.40(Predicted) |
Storage Condition | room temp |
RTECS | TX1498350 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
10 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
biological activity | 4-P-PDOT is a potent, selective and affinity antagonist of the melatonin receptor (MT2). The selectivity of 4-P-PDOT for MT2 was more than 300 times that of mt1. 4-P-PDOT can significantly counteract melatonin-mediated antioxidant effects (GSH/GSSG ratio, ERK phosphorylation, Nrf2 nuclear translocation, Nrf2 DNA binding activity). |
Target | MT2 receptor |
Cell Line: | HT-29 and HeLa cells. |
Concentration: | 30 min. |
Incubation Time: | 50 µM. |
Result: | Produced a negligible effect on cell viability induced by melatonin. Significantly reversed antioxidant effects mediated by Melatonin. Significantly reversed the changes in the levels of these GSH-related parameters. Significantly reversed the memory function of Melatonin-treated klotho mutant mice. |
Animal Model: | Klotho mutant mice treatment with Melatonin |
Dosage: | 0.5 mg/kg or 1.0 mg/kg |
Administration: | Intravenous injection |